6533-00-2 Usage
Description
Norgestrel is a synthetic progestin and a racemic mixture of dextronorgestrel and levonorgestrel, with levonorgestrel being the biologically active component. It is an excellent progestational and ovulation inhibiting steroid, used in various contraceptive formulations and has potential applications in other areas.
Uses
Used in Contraceptive Industry:
Norgestrel is used as a progestogen in oral contraceptives for its ovulation inhibiting properties, helping to prevent pregnancy.
Used in Intrauterine Device (IUD) Industry:
Norgestrel is used in intrauterine devices to prevent pregnancy in rats, showcasing its potential use in human contraceptive applications.
Used in Pharmaceutical Industry:
Norgestrel serves as a metabolite and an intermediate to the glucuronide metabolite of Levonorgestrel, playing a role in the development and understanding of progestin-based medications.
Used in Pain Management:
Norgestrel has potential applications as an analgesic and antipyretic, indicating its use in managing pain and reducing fever.
Safety Profile
Human reproductive effects byingestion and implant: menstrual cycle changes ordisorders and female fertility index changes. Anexperimental teratogen. Experimental reproductiveeffects. Questionable carcinogen with experimentalneoplastigenic data. An o
Check Digit Verification of cas no
The CAS Registry Mumber 6533-00-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,5,3 and 3 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6533-00:
(6*6)+(5*5)+(4*3)+(3*3)+(2*0)+(1*0)=82
82 % 10 = 2
So 6533-00-2 is a valid CAS Registry Number.
InChI:InChI=1/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21?/m0/s1
6533-00-2Relevant articles and documents
Preparation method of levonorgestrel
-
Paragraph 0025; 0027-0028; 0030-0031; 0033, (2020/09/20)
The invention discloses a preparation method of levonorgestrel, and belongs to the technical field of medicine preparation and processing. According to the method, 18-methylestra-2,5(10)-diene-3-methoxy-17-ketone is used as an initial raw material, and the levonorgestrel disclosed by the invention is prepared by virtue of two steps of ethynylation and hydrolysis. According to the preparation method of the levonorgestrel, the defects of a traditional process are overcome and reaction conditions are mild; the method is high in overall conversion rate, easy and convenient to operate, suitable forindustrial production and wide in market prospect.
Synthesis of 13-alkyl-gon-4-ones
-
, (2008/06/13)
The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
